This article only represents the author's own views.
A year ago, the imminent IPO by Chinese company LianBio (LIAN.US) wouldn’t have drawn much attention.
The biotech specialist’s offering is noteworthy for its large size, aiming to raise $345 million. But in the broadest terms, the company is just one of dozens of revenue-less, loss-making Chinese drug startups to publicly list in New York and Hong Kong over the last five years.
您已閱讀7%（431字），剩余93%（5634字）包含更多重要信息，訂閱以繼續(xù)探索完整內容，并享受更多專屬服務。